927.89
前日終値:
$818.77
開ける:
$869.43
24時間の取引高:
2.85M
Relative Volume:
3.39
時価総額:
$95.53B
収益:
$14.92B
当期純損益:
$4.42B
株価収益率:
22.61
EPS:
41.0422
ネットキャッシュフロー:
$3.79B
1週間 パフォーマンス:
+15.26%
1か月 パフォーマンス:
+22.37%
6か月 パフォーマンス:
+31.23%
1年 パフォーマンス:
+41.87%
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals Inc
|
927.89 | 95.53B | 14.92B | 4.42B | 3.79B | 41.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
558.88 | 141.65B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
221.72 | 88.52B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
892.87 | 56.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
370.33 | 41.89B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-01 | アップグレード | Argus | Hold → Buy |
| 2026-05-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2026-05-18 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-03-31 | 再開されました | Piper Sandler | Overweight |
| 2026-03-06 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | BofA Securities | Underperform → Buy |
| 2025-12-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 開始されました | HSBC Securities | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Pre-Markets in Red on Massive AI Spending Concerns - Zacks Investment Research
Pre-Markets Spooked on Questions Regarding AI, Oil Prices - Zacks Investment Research
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness - GlobeNewswire Inc.
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - GlobeNewswire Inc.
Facing Investing Fears - The Motley Fool
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat
Are You Overpaying For Regeneron Stock Versus Its Rivals? - Trefis
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen - MarketBeat
TD Cowen maintains Buy rating on Regeneron Pharmaceuticals, $980 price target - TradingView
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
EyePoint to halve workforce after experimental drug fails second late-stage trial - Reuters
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results - Yahoo Finance
How Much Upside Is Left In Regeneron Stock? - Yahoo Finance
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance Australia
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share - The Motley Fool
Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance UK
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types - GlobeNewswire Inc.
Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds - Yahoo Finance
Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data - Yahoo Finance
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report - Barchart.com
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
RBC raises target for Regeneron stock to USD 810.00 - ad-hoc-news.de
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Regeneron reports 84-week Phase III data for Pasatru in adult FOP - Yahoo Finance
Regeneron reports Pasatru data and Citi holds Regeneron stock - ad-hoc-news.de
Regeneron presents new long-term data for Pasatru - The Pharma Letter
Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95 - ad-hoc-news.de
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron’s New Drug Halts Rogue Bone Growth EffectivelyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP - Quiver Quantitative
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month - Stocktwits
Should Alliance Expansion Require Action From Regeneron (REGN) Investors? - Simply Wall Street
Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance Australia
Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative - Simply Wall Street
Why Regeneron (REGN) is a Top Value Stock for the Long-Term - Zacks Investment Research
Regeneron Pharma Is Maintained at Sector Perform by RBC Capital - Moomoo
What Is Going On With Regeneron Stock? - Trefis
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
Regeneron Pharmaceuticals Inc (REGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MURPHY ANDREW J | Co-Chief Scientific Officer |
Oct 14 '26 |
Sale |
772.70 |
4,147 |
3,204,376 |
47,833 |
| MURPHY ANDREW J | Officer |
Oct 14 '26 |
Proposed Sale |
772.70 |
4,147 |
3,204,380 |
0 |
| McCourt Marion | Officer |
Sep 03 '26 |
Proposed Sale |
857.00 |
1,131 |
969,267 |
0 |
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| McCourt Marion | EVP Commercial |
Sep 02 '26 |
Sale |
850.00 |
1,215 |
1,032,750 |
13,134 |
| McCourt Marion | Officer |
Sep 02 '26 |
Proposed Sale |
850.00 |
1,215 |
1,032,750 |
0 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Proposed Sale |
850.00 |
400 |
340,000 |
0 |
| LAROSA JOSEPH J | EVP General Counsel and Secret |
Aug 19 '26 |
Option Exercise |
381.92 |
12,282 |
4,690,741 |
45,392 |
大文字化:
|
ボリューム (24 時間):